pembrolizumab
merck
['keynote 189']
5year updated results of keynote 189 presented at #esmo2022. we continue to see a benefit despite an almost 60 % cross over!! spectacular! 
A dedicated conference for oncology held under the theme "Access. Educate. Collaborate"